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Abstract
Purpose: Many radioligands have been explored for imaging the 18-kDa translocator protein
(TSPO), a diagnostic and therapeutic target for inflammation and cancer. Here, we investigated
the TSPO radioligand [18F]DPA-714 for positron emission tomography (PET) imaging of cancer
and inflammation.
Procedures: [18F]DPA-714 PET imaging was performed in 8 mouse and rat models of breast
and brain cancer and 4 mouse and rat models of muscular and bowel inflammation.
Results: [18F]DPA-714 showed different uptake levels in healthy organs and malignant tissues of
mice and rats. Although high and displaceable [18F]DPA-714 binding is observed ex vivo,
TSPO-positive PET imaging of peripheral lesions of cancer and inflammation in mice did not
show significant lesion-to-background signal ratios. Slower [18F]DPA-714 metabolism and
muscle clearance in mice compared to rats may explain the elevated background signal in
peripheral organs in this species.
Conclusion: Although TSPO is an evolutionary conserved protein, inter- and intra-species
differences call for further exploration of the pharmacological parameters of TSPO radioligands.
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Introduction
The 18-kDa translocator protein (TSPO) is a member of the
evolutionary conserved transporter protein family [1]. In
animals, TSPO is primarily located on the outer
mitochondrial membrane of organs involved in steroid
synthesis such as the adrenal glands, testis and ovaries,
and the pituitary glands [2]. In the central nervous
system (CNS), TSPO levels are dramatically enhanced
in immune cells such as microglia and reactive astrocytes
during neuroinflammation [3–7]. High levels of TSPO
expression have also been reported in macrophages and
monocytes in the periphery [5, 8, 9], as well as in breast,
colorectal, prostate, ovarian, brain, and liver cancer cell
lines [10]. The pattern of TSPO expression suggests that
this protein plays a role in the modulation of immunity,
inflammation, and cell proliferation. TSPO is thus a
suitable biomarker candidate for a number of inflamma-
tory diseases and cancer [11], and it has also been
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explored as a prognostic marker [12, 13] and a
therapeutic target [7, 14–16]. As a result, TSPO has
generated much interest as an imaging target, and a large
number of TSPO radioligands have been synthesized for
positron emission tomography (PET) imaging including
[ 1 1C ]PK11195 , [ 1 1C ]DAA1106 , [ 1 1C ]PBR28 ,
[18F]PBR06, [11C]SSR180575, and [18F]DPA-714 [3,
17, 18].
Successful preclinical imaging evaluations have triggered
the clinical use of several TSPO radioligands in small
cohorts of patients [19]. The majority of these preclinical
studies investigated TSPO PET radiotracers in models of
neuroinflammation (e.g., Alzheimer’s disease [20], stroke
[21], multiple sclerosis [22], and glioma [23, 24]), generally
in the rat due to the small size of the mouse brain. However,
recent reports on the imaging of peripheral TSPO expression
in pulmonary, liver, muscle, and bowel inflammation [25–
29] and in breast cancer xenografts [30, 31] have increased
the interest in using TSPO ligands for imaging peripheral
inflammation and cancer. The emergence of TSPO as a
popular target for molecular imaging of major pathologies
fosters the testing and validation of TSPO PET radioligands
in an increasing number of animal models. However, the
recent revelation that, in humans, a significant proportion of
individuals (~14 %) who show in vitro specific binding for
[11C]PK11195 do not bind [11C]PBR28 [32], and the lack of
a clear causal relationship between in vitro affinity and
in vivo binding of different TSPO radioligands in other
species [33] raises legitimate concerns on the relevance of
preclinical TSPO imaging for translational purposes.
The TSPO radioligand [18F]DPA-714 has been shown to
possess excellent specificity and imaging performance in rat
models of acute neuroinflammation, and initial evaluation in
seven heal thy human volunteers confirmed its
biodistribution profile [34, 35]. [18F]DPA-714 is also the
radioligand for PET imaging of TSPO that was selected for
multicenter studies by the European consortium INMiND
(imaging of neuroinflammation in neurodegenerative dis-
eases) [36]. More recently, Lavisse et al. [37] reported that
its binding in healthy human volunteers is influenced by the
subject’s TSPO genotype (i.e., high, low, and mixed-affinity
binders). In the present study, we investigate the
biodistribution of [18F]DPA-714 and its ability to highlight
TSPO expression in different mouse and rat models of
cancer and peripheral inflammation.
Materials and Methods
Radiotracer Synthesis
N ,N -D i e t h y l - 2 - ( 2 - ( 4 - ( 2 - f l u o r o e t h o x y ) p h e n y l ) - 5 , 7 -
dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (DPA-714) was
labeled with fluorine-18 at its 2-fluoroethyl terminal using a
tosyloxy-for-fluorine nucleophilic aliphatic substitution slightly
modified from a previously published procedure [38–40].
Typically, from a 37 GBq [18F]fluoride batch, 5.6–7.4 GBq of
[18F]DPA-714 with 995 % chemical and radiochemical purity was
routinely obtained in 85 to 90 min with specific radioactivities
(SRA) ranging from 62 to 244 GBq/μmol. Final formulation was
adjusted in order to provide [18F]DPA-714 batches with high
radioactive concentrations, allowing thus the use of the radiotracer
in multiple and consecutive imaging sessions scheduled on a same
day.
Animal Models
All experiments were conducted in accordance with the European
Union regulations on animal research. MDA-MB-231 and MCF-7
human breast cancer cell lines were purchased from ATCC-LGC
Standards. Suspended in a 1:1 volume ratio of DMEM and
MatrigelTM (BD Biosciences, Le Pont de Claix, France), 5×106
cells were subcutaneously injected into the flanks of female nude
NMRI mice (Elevage Janvier, Le Genest Saint Isle Saint Berthevin,
France). The mice inoculated with MCF-7 cells were implanted
with a 17β-estradiol pellet (0.72 mg/pellet, 60-day release,
Innovative Research of America, Sarasota, FL, USA) under their
dorsal skin 24 h before tumor inoculation. The primary HBCx-12B
xenografts were established on female nude NMRI mice by
surgically implanting a small piece of a freshly resected HBCx-
12B tumor obtained from a donor mouse bearing a patient-derived
tumor (Institut Curie, Paris, France) [41]. The PyMT tumor model
was established in female FVB/NRj mice (Elevage Janvier, Le
Genest Saint Isle Saint Berthevin, France) by subcutaneously
implanting a small piece of a freshly resected MMTV-PyMT tumor
from the donor animal’s mammary fat pad. Intracranial tumor
development consisting in a stereotactic slow infusion (over 5 min)
of 1 μl of cell solution was performed on female Wistar rats and
female NMRI nude mice with the administration of 2×105 9L rat
glioma cells (stereotactic coordinates for nude mice were 2.5 mm
lateral to bregma and 3 mm from the dural surface). In addition,
2×106 9L cells were injected subcutaneously into a different group
of Wistar rats to induce peripheral 9L tumors. For the peripheral
inflammation model, 1 μl turpentine oil was injected intramuscu-
larly into the right inner thigh of female nude NMRI mice and 10 μl
into Wistar rats. Imaging of these acute inflammatory lesions was
conducted 24 h postinduction. The inflammatory bowel disease
model of colitis in C57BL/6 mice and Wistar rats was established
by introducing 2.5 % of dextran sulfate sodium (DSS) daily in the
animals’ drinking water for 7–8 days.
PET Imaging and Analysis
All PET acquisitions were conducted on a Focus 220 preclinical PET
system (Siemens, Knoxville, TN, USA). [18F]DPA-714 was i.v. injected
at a dose of 0.22±0.04MBq/g of bodyweight (bw) and 0.06±0.03MBq/g
bw into the tail vein of 56 mice (mean body weight 32.3±3.9 g; among
which 16 mice bore bilateral HBCx-12B s.c. tumors and 5 mice bore
bilateralMDA-MB-231 s.c. tumors) and 19 rats (mean bodyweight 376.8
± 58.4 g; among which 4 rats bore bilateral s.c. 9L tumors), respectively.
After decay correcting for the time gap between [18F]DPA-714 delivery,
injection and imaging for each animal, as well as taking into account the
batch-to-batch variation in specific radioactivity, the mean pmol of DPA-
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714 per g of body weight was calculated to be 27.0±20.3 for mice (range
3.9–83.2 pmol/g) and 7.7±11.4 for rats (range 0.7–36.4 pmol/g).
Immediately following radiotracer administration, the animals were
placed in a warm chamber set to 30 °C. At 30 min postinjection, the
animals were anesthetized using a 2–3 % isoflurane/oxygen mixture and
positioned on the imaging bed for a 30-min static PET acquisition (2
frames, 15 min each). Sinograms generated from these emission scans
were normalized and corrected for scatter, attenuation, and radioactivity
decay. Fourier rebinning (FORE) and an iterative 2D ordered subset
expectation maximization (OSEM) algorithm (16 subsets, 4 iterations)
was applied for image reconstruction. Data visualization, contouring, and
analysis were performed using the Anatomist BrainVISA software
package (http://www.brainvisa.info) using the 2nd frame of the PET
acquisition (45–60 min post tracer injection). Regions of interests (ROIs)
were drawnmanually on the organs and tissues of interest. Specifically for
muscle, the ROIs were placed on either the upper thigh or arm. All data is
expressed as the mean±standard deviation. Pharmacokinetics analysis
was performed by fitting a bi-exponential (two-compartment) model to
the blood time-activity curves (TACs) for each animal and calculating the
distribution half-life (t1/2α) and elimination half-life (t1/2β) of [
18F]DPA-
714 (assuming no metabolism). [18F]DPA-714 uptake was expressed as
%ID/g, lesion-to-muscle ratios of%ID/g, aswell as using the standardized
uptake value (SUV) calculated as (activity/g of tissue)/[(injected activity)/
(g of body weight)].
Metabolite Analysis and Measurement
of [18F]DPA-714 in Plasma and Muscle
Plasma andmuscle samples were obtained from 4 female FVBmice (21
±1 g each) and 4 maleWistar rats (306±69 g) which had received an i.v.
injection of 0.74±0.07 MBq/g bw and 0.14±0.03 MBq/g bw of
[18F]DPA-714, respectively, 60 min before kill. In order to detect the
intact form of [18F]DPA-714 in plasma andmuscle at 60min p.i. in both
species, the injected dose per body weight was 5.4-fold higher in mice.
The radioactivity in the plasma andmuscle samples wasmeasured using
a cross-calibrated gamma counter (Cobra Quantum D5003, Perkin
Elmer, Waltham, MA, USA). [18F]DPA-714 was quantified using a
previously published tissue extraction and HPLC analysis plus counting
method [42]. The radioactivity associated with [18F]DPA-714 was
expressed as a fraction of the summed radioactivity associated with all
radioactive peaks recorded on the radiochromatograms. All data was
expressed as %ID/g, SUV, and mouse-to-rat ratios of SUV.
Statistical Analysis
All statistical comparisons were performed using SPSS Statistics 22
software (IBM, Armonk, NY, USA) and the independent samples
unequal variance t test.
Results
[18F]DPA-714 Uptake in Neoplastic
and Inflammatory Lesions
The ability of [18F]DPA-714 to detect, visualize, and
accumulate in cancer and inflammation lesions was
evaluated in C57BL/6 and NMRI nude mice, as well as
Wistar rats in a total of 8 different tumor models and 4
inflammatory models (Table 1). The uptake of [18F]DPA-
714 in peripheral tumors was higher in mice than in rats
(0.85±0.36 %ID/g of tissue, n=61, versus 0.23±0.04 %ID/g
of tissue, n=8). However, due to the low peripheral tissue
background signal, the lesions were much more easily
identifiable in rats (Fig. 1) and the tumor-to-muscle ratios
were significantly higher in rats than in mice (13.9±1.8
compared to 1.2±0.2). When normalized by the animals’
body weight, the mean SUV of subcutaneous tumors in mice
was 0.27±0.09 and that of rat was 0.71±0.22. These
differences were independent of the SRA of [18F]DPA-
714 at time of image acquisition (45 min postinjection) as
shown in Fig. 2. Here, we investigated a subset of
animals and tumors, for which the SRA values for
[18F]DPA-714 from 7 separate productions used for the
36 PET imaging sessions ranged from 44 to 1732 mCi/
μmol. The SRA values (decay corrected to 45 min p.i.)
showed no correlation with tracer uptake values and
tumor-to-muscle ratios in 50 different tumors (Fig. 2).
Similarly, the uptake of [18F]DPA-714 in the two
peripheral inflammatory models investigated were higher
in mice than in rats. However, the lesion-to-control ratios
were significantly higher in rats (9.1±0.8) than in mice
(1.1±0.6). Specifically, the control regions employed were
the healthy muscle contralateral to the turpentine oil-
induced inflammation site for the muscle inflammation
model and the distal colon in healthy animals for the
inflammatory bowel disease model. It is noteworthy that
previous results showed significant and displaceable
[18F]DPA-714 binding ex vivo in all four subcutaneously
implanted mouse tumor models investigated here (PyMT,
MCF-7, HBCx-12B, and MDA-MB-231) [43]. In contrast,
intracranially implanted tumors were easily detectable in
both mice and rats. Using a mirror ROI contralateral to
the tumor area as control, the cerebral tumor lesion-to-
control ratios were similar between the two species (2.3
±0.3 in mice and 3.1±0.9 in rats), confirming the
feasibility of utilizing [18F]DPA-714 for imaging of CNS
lesions in both mice and rats.
Biodistribution of [18F]DPA-714 in Mice and Rats
Figure 3a and Supplementary Fig. S2 show the uptake of
[18F]DPA-714 at steady state (measured at 45 to 60 min
postinjection using the PET data set) in organs and tissues of
healthy NMRI nude mice and Wistar rats. Compared to rats,
mice presented a statistically higher mean %ID/g of tissue in
all organs and tissues investigated; the ratios of mean %ID/g
of tissue of uptake between mice (n=5) and rats (n=4) were
4.4 (heart), 7.7 (lungs), 19.2 (liver), 4.0 (spleen), 10.1
(kidneys), 7.2 (muscle), and 6.2 (brain). The independent
samples t test showed that the statistical difference in
accumulation at steady state in mice compared to rats was
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higher in the peripheral organs (pG0.001) compared to the
brain (p=0.002). This difference is not due to the higher dose
of radioactivity (i.e., [18F]DPA-714) normalized to body
weight administered to mice compared to rats (0.17
±0.06 MBq/g bw versus 0.03±0.01 MBq/g bw), or the
amount of DPA-714 administered to mice (22.3±7.8 pmol/g
bw) compared to rats (0.9±0.1 pmol/g bw). In fact, in the
muscle, an organ of low TSPO expression in both species,
the TACs (Supplementary Fig. S3) acquired from 0 to 60–
70 min following i.v. administration of [18F]DPA-714
showed no correlation between the uptake and the injected
dose per body weight of total DPA-714 (radiolabeled and
non-radiolabeled) in the range of 2.7 to 36.4 pmol/g.
However, a clear difference in the muscle uptake levels of
the tracer between the two species exists. Figure 3b and c
shows the TACs for 4 additional healthy tissues and organs
Fig. 1 Representative PET images illustrating the uptake of [18F]DPA-714 at steady state (45 to 60 min postinjection) in
different mouse and rat models of cancer and inflammation. Yellow arrows point to the lesions, and the white bar represents
1 cm.
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including the blood, kidney, liver, and spleen in the two
species during the first 60 min of [18F]DPA-714 uptake. It
can be observed that both the tracer distribution and
elimination half-lives are much longer in mice (t1/2α=15.6
±2.8 min, t1/2β=242.2±955.9 min, R
2=0.97±0.02) compared
to rats (t1/2α=0.3±0.1 min, t1/2β=31.2±3.6 min, R
2=0.98
±0.00).
Metabolism of [18F]DPA-714 in Mice and Rats
Ex vivo radio-HPLC analysis of the mouse and rat plasma
and muscle performed at 60 min postinjection showed
species-dependent differences in radiotracer clearance and
metabolism. Specifically, the proportions of intact
[18F]DPA-714 detected in the mouse and rat muscle were
97.3±1.7 % and 85.3±6.2 % of the total radioactivity,
respectively (p=0.026). Similarly in plasma, the propor-
tions of intact [18F]DPA-714 detected were 52.3±18.4 %
and 16.0±5.1 % of total radioactivity for mice and rats,
respectively (p=0.025). These statistically significant dif-
ferences illustrate the faster metabolism of [18F]DPA-714
in rats compared to mice. In addition, direct comparison
of the total amount of radioactivity measured in the
mouse and rat muscle shows that the overall mouse
muscle radioactivity is higher than in rat (mean muscle
SUV corresponding to 0.67±0.73 and 0.43±0.13, respec-
tively), while the total radioactivity measured in plasma
was higher in rat than in mouse (mean plasma SUV of
0.21±0.14 vs. 0.07±0.07). These observations illustrate that
despite a faster clearance of overall radioactivity
([18F]DPA-714 plus its radiometabolites) from mouse
plasma compared to rats, the muscle radioactivity build-
up is significantly higher in mice. In fact, the muscle-to-
plasma ratio for total radioactivity expressed as SUV was
calculated to be 10.2±4.2 in mice and 2.5±1.2 in rats
(p=0.029, Fig. 4). As a result, the higher amount of total
radioactivity and intact [18F]DPA-714 present at 60 min
Fig. 2 No correlation was found between the degree of
[18F]DPA-714 uptake in subcutaneous mouse tumors or the
tumor-to-muscle ratio and the specific radioactivity of
[18F]DPA-714 at 45 min postinjection. The data presented
was obtained from PET images from 36 independent imaging
sessions (7 independent radiotracer productions) and 50
tumors.
Fig. 3 a Distribution and uptake of [18F]DPA-714 (%ID/g of
tissue) in organs of healthy mice and rats at 45 to 60 min
postinjection measured from the PET data sets. In all
peripheral organs investigated, the difference in tracer
distribution between mice and rats was highly statistically
significant (denoted with **pG0.001). In the brain, the p value
calculated following an independent samples t test per-
formed on the mice vs. rats values was 0.002 (denoted with
*). The same data plotted as SUV can be found in
Supplementary Figure S2. b Time-activity curves (TACs)
obtained from the blood, kidney, liver, and spleen of mice
(n=3) and c rats (n=2) showing a more prolonged vascular
half-life of [18F]DPA-714 (and possibly its radiometabolites) in
mice as well as a higher level of radioactivity detected in all
organs included in this analysis over the first 60 min
postinjection.
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p.i. in the mouse muscle compared to rat muscle is
believed to be a significant contributor to the low contrast
observed between the peripheral tumor/inflammation areas
and the surrounding healthy muscle tissue in the PET
images acquired in mice.
Discussion
The present results show that even though TSPO is
evolutionary conserved and its expression is boosted in
inflammation and cancer in both mice and rats, the
in vivo imaging performance of [18F]DPA-714 is clearly
species dependent. In mice, in two peripheral disease
models of inflammation (n=6) and five models of
subcutaneously implanted tumors (n=5 to 32), no
significant target-to-background ratios of [18F]DPA-714
were measured in peripheral murine disease tissues
in vivo using PET imaging despite a high TSPO
expression relative to control regions had been measured
using Western blot and ex vivo autoradiography [43].
However, the same disease type in the same tissue (i.e.,
subcutaneously implanted breast or glioma tumors,
turpentine oil-induced peripheral inflammation and in-
flammatory bowel disease) provided a high uptake of
[18F]DPA-714 only in rats (Table 1, Fig. 1). The higher
overall radioactivity signal measured in the mouse
muscle and the higher percentage of intact radioligand
detected in mouse plasma and muscle compared to rat
suggest that plasma metabolism and muscle clearance of
[18F]DPA-714 are delayed in mice relative to rats. The
longer vascular half-life profile of [18F]DPA-714 and its
radiometabolites in mice compared to rats was also
confirmed in vivo by TACs obtained in the first
60 min post tracer administration (Fig. 3b, c). Slow
plasma metabolism and pharmacokinetics of [18F]DPA-
714 may cause a build-up of radioactivity and result in a
high non-specific background signal, as seen in the PET
images in mice, decreasing lesion-to-background contrast.
This hypothesis is supported by previously published
results which demonstrated minimal level of [18F]DPA-
714 binding ex vivo in mouse muscle tissue compared to
high TSPO-expressing tumor tissues [43]. A possible
explanation of why this build-up of free radioligand
would spare the brain could be that [18F]DPA-714 and
most of its radiometabolites do not easily cross the intact
blood brain barrier. This explanation is consistent with
the low background signal associated with [18F]DPA-714
in the healthy brain [35, 44]. Other possible factors that
can contribute to the species differences observed in this
study include differential binding affinity of [18F]DPA-
714 for mouse and rat TSPO, as well as potential
presence of [18F]DPA-714-binding sites in mice not
related to TSPO. In addition, preclinical disease models
often require the use of immune-compromised animals,
such as nude mice, in this study as hosts to human-
derived cancer cells. Physiological differences stemmed
from differing immune systems between these immune-
compromised animals and their wild-type counterparts
may also be a contributor to the observed differential
radiotracer performance. As a result, further investiga-
tions are necessary to fully understand and characterize
the differences in clearance and metabolism of
[18F]DPA-714 observed in mice and rats, as is also
important to determine whether other currently available
TSPO radioligands share the same species-dependent
pharmacokinetics and metabolism characteristics as
[18F]DPA-714.
Conclusions
This report confirms the suitability of [18F]DPA-714 as an
effective PET imaging probe for cancer and inflammation in
both the CNS and periphery of rats and CNS lesions in mice.
However, significant differences in species-dependent me-
tabolism and muscle accumulation of [18F]DPA-714 caution
the use of this radiotracer, and possibly other TSPO-targeted
probes, for imaging TSPO-positive peripheral lesions in
mice.
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Fig. 4 Muscle-to-plasma SUV ratios of total radioactivity
and [18F]DPA-714 measured at 60 min postinjection in mice
and rats using HPLC-based radiochromatography. The data
bars represent the mean and standard deviation calculated
from four animals. * denotes pG0.05.
J. Zheng et al.: PET Imaging Using [18F]DPA-714 in Rodents 133
References
1. Fan J, Lindemann P, Feuilloley MG, Papadopoulos V (2012) Structural
and functional evolution of the translocator protein (18 kDa). Curr Mol
Med 12:369–386
2. Papadopoulos V, Baraldi M, Guilarte TR et al (2006) Translocator
protein (18kDa): new nomenclature for the peripheral-type benzodiaz-
epine receptor based on its structure and molecular function. Trends
Pharmacol Sci 27:402–409
3. Chauveau F, Boutin H, Van Camp N et al (2008) Nuclear imaging of
neuroinflammation: a comprehensive review of [11C]PK11195 chal-
lengers. Eur J Nucl Med Mol Imaging 35:2304–2319
4. Doorduin J, de Vries EF, Dierckx RA, Klein HC (2008) PET imaging
of the peripheral benzodiazepine receptor: monitoring disease progres-
sion and therapy response in neurodegenerative disorders. Curr Pharm
Des 14:3297–3315
5. Venneti S, Lopresti BJ, Wiley CA (2006) The peripheral benzodiaze-
pine receptor (translocator protein 18kDa) in microglia: from pathology
to imaging. Prog Neurobiol 80:308–322
6. Maeda J, Higuchi M, Inaji M et al (2007) Phase-dependent roles of reactive
microglia and astrocytes in nervous system injury as delineated by imaging
of peripheral benzodiazepine receptor. Brain Res 1157:100–111
7. Rupprecht R, Papadopoulos V, Rammes G et al (2010) Translocator
protein (18 kDa) (TSPO) as a therapeutic target for neurological and
psychiatric disorders. Nat Rev Drug Discov 9:971–988
8. van der Laken CJ, Elzinga EH, Kropholler MA et al (2008) Noninvasive
imaging of macrophages in rheumatoid synovitis using 11C-(R)-PK11195
and positron emission tomography. Arthritis Rheum 58:3350–3355
9. Fujimura Y, Hwang PM, Trout H III et al (2008) Increased peripheral
benzodiazepine receptors in arterial plaque of patients with atherosclerosis:
an autoradiographic studywith [3H]PK 11195. Atherosclerosis 201:108–111
10. Corsi L, Geminiani E, Baraldi M (2008) Peripheral benzodiazepine
receptor (PBR) new insight in cell proliferation and cell differentiation
review. Curr Clin Pharmacol 3:38–45
11. Campanella M (2012) Editorial: The physiology and pharmacology of
the mitochondrial 18 kDa translocator protein (TSPO): an emerging
molecular target for diagnosis and therapy. Curr Mol Med 12:355
12. Hardwick M, Fertikh D, Culty M et al (1999) Peripheral-type
benzodiazepine receptor (PBR) in human breast cancer: correlation of
breast cancer cell aggressive phenotype with PBR expression, nuclear
localization, and PBR-mediated cell proliferation and nuclear transport
of cholesterol. Cancer Res 59:831–842
13. Galiegue S, Casellas P, Kramar A et al (2004) Immunohistochemical
assessment of the peripheral benzodiazepine receptor in breast cancer
and its relationship with survival. Clin Cancer Res 10:2058–2064
14. Mendonca-Torres MC, Roberts SS (2013) The translocator protein
(TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and
sensitizes to chemotherapy treatment in pre- and post-relapse neuro-
blastoma cell lines. Cancer Biol Ther 14:319–326
15. Austin CJ, Kahlert J, Kassiou M, Rendina LM (2013) The translocator
protein (TSPO): a novel target for cancer chemotherapy. Int J Biochem
Cell Biol 45:1212–1216
16. Papadopoulos V, Lecanu L (2009) Translocator protein (18 kDa) TSPO:
an emerging therapeutic target in neurotrauma. Exp Neurol 219:53–57
17. Dolle F, Luus C, Reynolds A, Kassiou M (2009) Radiolabelled
molecules for imaging the translocator protein (18 kDa) using positron
emission tomography. Curr Med Chem 16:2899–2923
18. Damont A, Roeda D, Dolle F (2013) The potential of carbon-11 and
fluorine-18 chemistry: illustration through the development of positron
emission tomography radioligands targeting the translocator protein 18
kDa. J Label Compd Radiopharm 56:96–104
19. Winkeler A, Boisgard R, Martin A, Tavitian B (2012) Radioisotopic
imaging of neuroinflammation. J Nucl Med 51:1–4
20. Maeda J, Zhang MR, Okauchi T et al (2011) In vivo positron emission
tomographic imaging of glial responses to amyloid-beta and tau
pathologies in mouse models of Alzheimer's disease and related
disorders. J Neurosci 31:4720–4730
21. Martin A, Boisgard R, Theze B et al (2009) Evaluation of the PBR/
TSPO radioligand [18F]DPA-714 in a rat model of focal cerebral
ischemia. J Cereb Blood Flow Metab 30:230–241
22. Abourbeh G, Theze B, Maroy R et al (2012) Imaging microglial/macrophage
activation in spinal cords of experimental autoimmune encephalomyelitis rats
by positron emission tomography using the mitochondrial 18 kDa translocator
protein radioligand [18F]DPA-714. J Neurosci 32:5728–5736
23. Winkeler A, Boisgard R, Awde AR et al (2012) The translocator protein
ligand [18F]DPA-714 images glioma and activated microglia in vivo.
Eur J Nucl Med Mol Imaging 39:811–823
24. Awde AR, Boisgard R, Theze B et al (2013) The translocator protein
radioligand [18F]DPA-714 monitors antitumor effect of erufosine in a
rat 9L intracranial glioma model. J Nucl Med 54:2125–2131
25. Kumata K, Yui J, Hatori A et al (2011) Synthesis and evaluation of
novel carbon-11 labeled oxopurine analogues for positron emission
tomography imaging of translocator protein (18 kDa) in peripheral
organs. J Med Chem 54:6040–6049
26. Hatori A, Yui J, Yamasaki T et al (2012) PET imaging of lung
inflammation with [18F]FEDAC, a radioligand for translocator protein
(18 kDa). PLoS One 7, e45065
27. Xie L, Yui J, Hatori A et al (2012) Translocator protein (18 kDa), a
potential molecular imaging biomarker for non-invasively
distinguishing non-alcoholic fatty liver disease. J Hepatol 57:1076–
1082
28. Bernards N, Pottier G, Theze B et al. (2014) In vivo evaluation of
inflammatory bowel disease with the aid of microPET and the
translocator protein 18 kDa radioligand [18F]DPA-714. Mol Imaging
Biol
29. Wu C, Yue X, Lang L et al (2014) Longitudinal PET imaging of
muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and
differentiation with tumors. Theranostics 4:546–555
30. Wyatt SK, Manning HC, Bai M et al (2009) Molecular imaging of the
translocator protein (TSPO) in a pre-clinical model of breast cancer.
Mol Imaging Biol 12:349–358
31. Vasdev N, Green DE, Vines DC et al (2013) Positron-emission
tomography imaging of the TSPO with [18F]FEPPA in a preclinical
breast cancer model. Cancer Biother Radiopharm 28:254–259
32. Owen DR, Howell OW, Tang SP et al (2010) Two binding sites for
[3H]PBR28 in human brain: implications for TSPO PET imaging of
neuroinflammation. J Cereb Blood Flow Metab 30:1608–1618
33. Kreisl WC, Fujita M, Fujimura Y et al (2009) Comparison of [11C]-
(R)-PK 11195 and [11C]PBR28, two radioligands for translocator
protein (18 kDa) in human and monkey: implications for positron
emission tomographic imaging of this inflammation biomarker.
Neuroimage 49:2924–2932
34. Chauveau F, Van Camp N, Dolle F et al (2009) Comparative evaluation
of the translocator protein radioligands [11C]DPA-713, [18F]DPA-714,
and [11C]PK11195 in a rat model of acute neuroinflammation. J Nucl
Med 50:468–476
35. Arlicot N, Vercouillie J, Ribeiro MJ et al (2011) Initial evaluation in
healthy humans of [18F]DPA-714, a potential PET biomarker for
neuroinflammation. Nucl Med Biol 39:570–578
36. Jacobs AH, Tavitian B (2012) Noninvasive molecular imaging of
neuroinflammation. J Cereb Blood Flow Metab 32:1393–1415
37. Lavisse S, Garcia-Lorenzo D, Peyronneau MA et al. (2015) Optimized
quantification of TSPO radioligand 18F-DPA-714 uptake in the brain of
genotyped healthy volunteers. J Nucl Med
38. James ML, Fulton RR, Vercoullie J et al (2008) DPA-714, a new
translocator protein-specific ligand: synthesis, radiofluorination, and
pharmacologic characterization. J Nucl Med 49:814–822
39. Damont A, Hinnen F, Kuhnast B et al (2008) Radiosynthesis of
[18F]DPA-714, a selective radioligand for imaging the translocator
protein (18 kDa) with PET. J Label Compd Radiopharm 51:286–292
40. Kuhnast B, Damont A, Hinnen F et al (2011) [18F]DPA-714,
[18F]PBR111 and [18F]FEDAA1106-selective radioligands for imag-
ing TSPO 18 kDa with PET: automated radiosynthesis on a
TRACERLAb FX-FN synthesizer and quality controls. Appl Radiat
Isot 70:489–497
41. Marangoni E, Vincent-Salomon A, Auger N et al (2007) A new model
of patient tumor-derived breast cancer xenografts for preclinical assays.
Clin Cancer Res 13:3989–3998
42. Peyronneau MA, Saba W, Goutal S et al (2013) Metabolism and
quantification of [18F]DPA-714, a new TSPO positron emission
tomography radioligand. Drug Metab Dispos 41:122–131
43. Zheng J, Boisgard R, Siquier-Pernet K et al (2011) Differential
expression of the 18 kDa translocator protein (TSPO) by neoplastic
and inflammatory cells in mouse tumors of breast cancer. Mol Pharm
8:823–832
44. Vicidomini C, Panico M, Greco A et al. (2014) In vivo imaging and
characterization of [F]DPA-714, a potential new TSPO ligand, in mouse
brain and peripheral tissues using small-animal PET. Nucl Med Biol
134 J. Zheng et al.: PET Imaging Using [18F]DPA-714 in Rodents
